| ID | Sequence | Length | GC content |
|---|---|---|---|
| lnc-PFKFB3-453:1 | GAUUGUAAGUUUCCUGAGGCCUCCCUAGAAGCUGAGCAGAUGCCAGCAC… | 3086 nt | 0.4799 |
| lnc-PFKFB3-453:2 | AGAUAUGGAGUUACCAGUAAGGAGCUCCACCGUGACUCUCCUCCCUGCU… | 2966 nt | 0.4808 |
| lnc-PFKFB3-453:3 | AGAUAUGGAGUUACCAGUAAGGAGCUCCACCGUGACUCUCCUCCCUGCU… | 2967 nt | 0.4806 |
| lnc-PFKFB3-453:4 | CUUUUUUUAAGCUGAUAAUUUUAUAUCUAUGUAAGAUCUUCUGUUUCCU… | 226 nt | 0.4735 |
| lnc-PFKFB3-453:5 | GAACUUCACAUAUGAAGCCCCUCUCAUGUGUCAGGCACGGCGUCAGAUG… | 1290 nt | 0.4496 |
No relevant information is available at the moment.
A study in human patients identified the lnc-PFKFB3-453 as a key mRNA that is downregulated in myocardial fibrosis versus acute myocardial infarction and upregulated in heart failure versus myocardial fibrosis, with its expression validated by qPCR and electronic datasets [Wang et al. DOI:10.3389/fcvm.2021.664044].